Investigating the Knowledge Sharing among students in Pakistan

This paper’s goal is to empirically examine the impact of trust, attitude, and ICT Use on knowledge sharing among degree students of universities in Vehari. Self-efficacy theory was used as an underpinning theory to test the suggested model. A sample size of 120 students was selected to collect the primary data through survey from respondents. Correlation and multiple regression analysis were performed to test the hypotheses drawn from this study. The findings show that trust, attitude and ICT Use are the key factors in order to boost knowledge sharing amongst students. The results show that ICT Use is highly significant and correlated predictor of knowledge sharing. The study also discussed implications, limitations and future research recommendation that can be helpful both universities and researchers for further study

Factors Affecting Part-time Students Performance in Pakistan

This research is concerned about part-time student performance within higher educational institutions in Pakistan. Part-time students contain a significant share of the student population. In the perspective of working students as part-time studying, there are some significant factors that should be considered seriously to perform well. This research was examined to find the relationship of soft skills (motivation to learn, stress, time management) among part time-students’ performance in south Punjab of Pakistan. Primary data was collected from a sample of 140 part-time enrolled students. Correlation and regression analysis were tested in this research. The result showed that time management was the most significant factor of student performance. Same as stress has significant but negative correlation with student performance. The study concluded that these soft skills have significant importance with the part-time working student performance

Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh.

BACKGROUND:This study was conducted in Bangladeshi patients in an outpatient setting to support registration of Paromomycin Intramuscular Injection (PMIM) as a low-cost treatment option in Bangladesh. METHODOLOGY:This Phase IIIb, open-label, multi-center, single-arm trial assessed the efficacy and safety of PMIM administered at 11 mg/kg (paromomycin base) intramuscularly once daily for 21 consecutive days to children and adults with VL in a rural outpatient setting in Bangladesh. Patients ≥5 and ≤55 years were eligible if they had signs and symptoms of VL (intermittent fever, weight loss/decreased appetite, and enlarged spleen), positive rK39 test, and were living in VL-endemic areas. Compliance was the percentage of enrolled patients who received 21 daily injections over no more than 22 days. Efficacy was evaluated by initial clinical response, defined as resolution of fever and reduction of splenomegaly at end of treatment, and final clinical response, defined as the absence of new clinical signs and symptoms of VL 6 months after end of treatment. Safety was assessed by evaluation of adverse events. PRINCIPAL FINDINGS:A total of 120 subjects (49% pediatric) were enrolled. Treatment compliance was 98.3%. Initial clinical response in the Intent-to-Treat population was 98.3%, and final clinical response 6 months after end of treatment was 94.2%. Of the 119 subjects who received ≥1 dose of PMIM, 28.6% reported at least one adverse event. Injection site pain was the most commonly reported adverse event. Reversible renal impairment and/or hearing loss were reported in 2 subjects. CONCLUSIONS/SIGNIFICANCE:PMIM was an effective and safe treatment for VL in Bangladesh. The short treatment duration and lower cost of PMIM compared with other treatment options may make this drug a preferred treatment to be investigated as part of a combination therapy regimen. This study supports the registration of PMIM for use in government health facilities in Bangladesh. TRIAL REGISTRATION:ClinicalTrials.gov identifier: NCT01328457

Summary of adverse events.

<p>The Safety population includes all subjects who received ≥1 dose of study drug. Subjects with multiple occurrences of the same event are counted only once.</p><p>^a One event of pyrexia reported in an adult male at site 2 was not treatment emergent.</p><p>^b Grade 3 or 4 according to Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTEP-CTCAE) definition.</p><p>Summary of adverse events.</p

Adverse events.

<p>AE, adverse event.</p><p>Subjects with multiple occurrences of the same event are counted only once for a specific system organ class and preferred term.</p><p>^a One event of pyrexia reported in an adult male at site 2 was not treatment emergent.</p><p>Adverse events.</p

Efficacy results (ITT population).

<p>^a Initial clinical response was defined as the resolution of fever and the reduction of splenomegaly by palpation at EOT.</p><p>^b Final clinical response was defined as the absence of new clinical signs and symptoms of VL at 6 months after EOT.</p><p>Efficacy results (ITT population).</p

Patient disposition flow chart.

<p>Patient disposition flow chart.</p